In vitro antifungal activity of amphotericin B and 11 6 7 comparators against Aspergillus terreus species complex

Vaezi, A and Shokohi, T and Arastehfar, A and Fakhim, H and T. Hedayati, M and Khodavaisy, S and Rezaei Matehkolaei, A and Hagen, F and Badiee, P and Lass Flörl, C and Dannaoui, E and F. Meis, J and Badali, H (2017) In vitro antifungal activity of amphotericin B and 11 6 7 comparators against Aspergillus terreus species complex. Mycoses. pp. 1-9.

Preview

Text 807.pdf Download (948kB) | Preview

Abstract

Aspergillus terreus infections are difficult to treat because of the intrinsic resistance to 33 Research Center, School of Medicine, 34 Mazandaran University of Medical Sciences, amphotericin B, and higher mortality compared to infections caused by other Aspergillus 35 Sari, Iran. species. The aim of the present study was to determine the in vitro antifungal activity 36 Email: badalii@yahoo.com of amphotericin B and 11 comparators against clinical (n = 36) and environmental 37 Funding information (n = 45) A. terreus isolates. In vitro antifungal susceptibility was performed using the 38 Mazandaran University of Medical Sciences, CLSI M38--A2 procedure. Amphotericin B exhibited the highest MICs (MIC range, 39 Grant/Award Number: 2206 40 0.125--4 μg/mL; MIC90, 2 μg/mL), followed by terbinafine (MIC range, 0.002--1 μg/mL; 41 MIC90, 1 μg/mL). Only one isolate (1/81) showed amphotericin B MIC above the epi- 42 demiologic cut--off value (ECV; 4 μg/mL). None of the isolates had a MIC of≥ECV for 43 voriconazole, itraconazole and posaconazole. The reasons for the difference in am- 44 photericin B susceptibility patterns between studies remain unknown. The genetic and 45 species diversity, clinical, environmental and ecological factors in Terrei section on 46 various amphotericin B susceptibility profiles in different countries should be consid- 47 ered more as the main reasons associated with these differences.

Actions (login required)

View Item